TIL Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-2.540

+39.56%

-2.747

-36.42%

-2.950

-8.95%

Estimates Revision

The market is revising No Change the revenue expectations for Instil Bio, Inc. (TIL) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -62.92%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.76%

In Past 3 Month

Stock Price

Go Down

-62.92%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast TIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TIL is 125.00 USD with a low forecast of 125.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

125.00

Averages

125.00

High

125.00

Current: 0.000

Low

125.00

Averages

125.00

High

125.00

Baird

Outperform -> Neutral

downgrade

$180 -> $7

2026-01-06

New

Reason

Baird

Price Target

$180 -> $7

2026-01-06

New

downgrade

Outperform -> Neutral

Reason

Baird downgraded Instil Bio to Neutral from Outperform with a price target of $7, down from $180, after the company discontinued clinical development of AXN-2510.

Baird

Jack Allen

Outperform -> Neutral

downgrade

$180 -> $7

2026-01-06

New

Reason

Baird

Jack Allen

Price Target

$180 -> $7

2026-01-06

New

downgrade

Outperform -> Neutral

Reason

Baird analyst Jack Allen downgraded Instil Bio to Neutral from Outperform with a price target of $7, down from $180. The stock in midday trading is down 47%, or $5.79, to $6.50. Baird cites the discontinuation of AXN-2510 for the downgrade. Instil terminated its licenses with ImmuneOnco surrounding AXN-2510 and AXN-27M. The analyst is "disappointed" by the news, saying the early data for AXN-2510 was "encouraging." Further details surrounding the decision to discontinue to AXN-2510 are not being disclosed, the analyst tells investors in a research note.

H.C. Wainwright

Buy

maintain

$105 -> $125

2025-05-23

Reason

H.C. Wainwright

Price Target

$105 -> $125

2025-05-23

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Instil Bio to $125 from $105 and keeps a Buy rating on the shares after the company released Phase 1/2 dose escalation data for AXN-2510 in first-line non-small cell lung cancer. The firm increased its probability of approval to 35% from 25%.

H.C. Wainwright

Buy

downgrade

$110 -> $105

2025-05-22

Reason

H.C. Wainwright

Price Target

$110 -> $105

2025-05-22

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Instil Bio to $105 from $110 and keeps a Buy rating on the shares following the Q1 report. The firm says Pfizer's "lucrative" PD-1 x VEGF bispecific deal underscores the attractiveness of tumor-infiltrating lymphocytes. The rising values of these transactions should provide further confidence that the highly positive clinical impact of these PD-1/L1 x VEGF bispecifics is real, the analyst tells investors in a research note.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$110

2025-03-05

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$110

2025-03-05

Reiterates

Strong Buy

Reason

JMP Securities

Chris Muller

Hold

Reiterates

n/a

2025-02-13

Reason

JMP Securities

Chris Muller

Price Target

n/a

2025-02-13

Reiterates

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Instil Bio Inc (TIL.O) is -1.74, compared to its 5-year average forward P/E of -4.16. For a more detailed relative valuation and DCF analysis to assess Instil Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.16

Current PE

-1.74

Overvalued PE

0.47

Undervalued PE

-8.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.94

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.47

Undervalued EV/EBITDA

-8.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2725.49

Current PS

0.00

Overvalued PS

12414.25

Undervalued PS

-6963.27

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TIL News & Events

Events Timeline

No data

News

7.0

01-09PRnewswire

Instil Bio's Subsidiary Axion Discontinues AXN-2510 Development, Stock Plummets 45.81%

2.0

01-06Benzinga

Instil Bio Discontinues AXN-2510 Clinical Development, Stock Plummets 52.48%

9.0

01-06Benzinga

Alumis Inc. Shares Surge 132% After Successful Phase 3 Trial Results

People Also Watch

Frequently Asked Questions

What is Instil Bio Inc (TIL) stock price today?

The current price of TIL is 7.13 USD — it has decreased -3.52 % in the last trading day.

What is Instil Bio Inc (TIL)'s business?

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.

What is the price predicton of TIL Stock?

What is Instil Bio Inc (TIL)'s revenue for the last quarter?

Instil Bio Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Instil Bio Inc (TIL)'s earnings per share (EPS) for the last quarter?

Instil Bio Inc. EPS for the last quarter amounts to -2.01 USD, decreased -43.22 % YoY.

What changes have occurred in the market's expectations for Instil Bio Inc (TIL)'s fundamentals?

How many employees does Instil Bio Inc (TIL). have?

Instil Bio Inc (TIL) has 14 emplpoyees as of January 10 2026.

What is Instil Bio Inc (TIL) market cap?

Today TIL has the market capitalization of 48.36M USD.